Niagen Bioscience, Inc. 8K

Niagen Bioscience, Inc. announced its Q2 2026 financial results and cash-positive operations while launching a telehealth platform and a designated rare-disease pharmaceutical program, repurchasing stock, and outlining a 2026 investment-focused growth strategy.

On August 4, 2026, Niagen Bioscience, Inc. reported its second quarter 2026 results and strategic updates, highlighting net sales of $29.8 million (including $24.2 million from Tru Niagen), net income of $1.0 million and adjusted EBITDA of $3.0 million, positive operating cash flow of $1.6 million year-to-date, and quarter-end cash of $66.7 million, while also announcing the launch of the Niagen Plus telehealth platform, initiation of a pharmaceutical program with lead candidate NB4168 (which received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations for Ataxia-Telangiectasia), engagement of Evotec for preclinical and IND-enabling work, a stock repurchase of $2.8 million, appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, and providing 2026 outlook emphasizing strategic investment and expected growth in e-commerce and Niagen Plus from 2027.

Filing Facts

CIK

1386570

Ticker

-

Form

8K

Source Type

sec

Accession

0001386570-26-000042

Alert Tier

6